Allergy Therapeutics (LON:AGY) Reaches New 1-Year Low – Should You Sell?

Allergy Therapeutics plc (LON:AGY)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as GBX 6.50 and last traded at GBX 7, with a volume of 68370 shares changing hands. The stock had previously closed at GBX 7.

Allergy Therapeutics Stock Performance

The stock has a 50 day simple moving average of GBX 9.21 and a 200 day simple moving average of GBX 10.39. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The company has a market cap of £443.28 million, a price-to-earnings ratio of -7.22, a PEG ratio of -30.70 and a beta of 0.85.

Allergy Therapeutics (LON:AGY) last posted its earnings results on Tuesday, March 31st. The company reported GBX (0.38) earnings per share (EPS) for the quarter. The company had revenue of GBX 3,628 million during the quarter. Allergy Therapeutics had a negative net margin of 85.46% and a positive return on equity of 409.00%. As a group, analysts predict that Allergy Therapeutics plc will post -2.56 EPS for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.